d-dimer levels decreased in severe allergic asthma and chronic urticaria patients with the ...

17
ARZU DIDEM YALCIN, MD. ( 姚晶愛 ) Internal Medicine, Allergy and Clinical Immunology Academia S inica, Genomics Research Cent er, Taipei, Taiwan adidyal@yahoo. com adidyal@gat e. sinica. edu. tw

Upload: -arzu-didem-yalcin

Post on 08-Jul-2015

101 views

Category:

Health & Medicine


0 download

DESCRIPTION

ARZU DIDEM YALCIN

TRANSCRIPT

Page 1: D-DIMER LEVELS decreased  in severe allergic asthma and chronic urticaria patients with the  omalizumab treatment

ARZU DIDEM YALCIN, MD. (姚晶愛 )Internal Medicine, Allergy and Clinical ImmunologyAcademia Sinica, Genomics Research Center, Taipei, [email protected]@gate.sinica.edu.tw

Page 2: D-DIMER LEVELS decreased  in severe allergic asthma and chronic urticaria patients with the  omalizumab treatment

Biomaterials Research - Manfred Maitz

Page 3: D-DIMER LEVELS decreased  in severe allergic asthma and chronic urticaria patients with the  omalizumab treatment

Biomaterials Research - Manfred Maitz

Page 4: D-DIMER LEVELS decreased  in severe allergic asthma and chronic urticaria patients with the  omalizumab treatment

Biomaterials Research - Manfred Maitz

Page 5: D-DIMER LEVELS decreased  in severe allergic asthma and chronic urticaria patients with the  omalizumab treatment

Biomaterials Research - Manfred MaitzD-dimer

Page 6: D-DIMER LEVELS decreased  in severe allergic asthma and chronic urticaria patients with the  omalizumab treatment

Biomaterials Research - Manfred Maitz

GROUP-1 SEVERE ASTMA

 n:20

1A- BEFORE OMALIZUMAB  

1B- AFTER 4TH MONTH OMALIZUMAB  

1C-AFTER 8TH MONTH OMALIZUMAB

1D-AFTER 12TH MONTH OMALIZUMAB

Page 7: D-DIMER LEVELS decreased  in severe allergic asthma and chronic urticaria patients with the  omalizumab treatment

Biomaterials Research - Manfred Maitz

Figure 1: (Group I:SPA, n:20) D-Dimer levels (mean±SD). Group IA: 467.63±106.39. Group IB: 430.00 ± 92.90. Group IC: 401.21 ± 72.19. Group ID: 377.37 ± 62.33. Group IA, using desloratadin, inhalan forte doses steroid .We compared DD levels between groups: The significant DD difference was observed between group-IA and group-IC (p<0.05), (P=0.031); between group-IA and group-ID (p<0.05), (P=0.003); between group-IB and group-ID (p<0.05), (P=0.049); a significant positive correlation between age and ADY (p=0.043, r=0.468, p<0.05). In the group-ID there was a significant positive correlation between DD and age (p=0.034, r=0.488, p<0.05).

Page 8: D-DIMER LEVELS decreased  in severe allergic asthma and chronic urticaria patients with the  omalizumab treatment

Biomaterials Research - Manfred Maitz2A-1-BEFORE OMALIZUMAB-AKTIVE PHASE N:8

2A-2-BEFORE OMALIZUMAB- PASSIVE PHASE

2B-AFTER 4TH MONTH OMALIZUMAB

2C- AFTER 8TH MONTH OMALIZUMAB

2D- AFTER 12TH MONTH OMALIZUMAB

Page 9: D-DIMER LEVELS decreased  in severe allergic asthma and chronic urticaria patients with the  omalizumab treatment

Biomaterials Research - Manfred MaitzD-dimer

e 2: (Group II: CU, n:8) D-Dimer levels (mean±SD). Group IIA-1: 506.25 ± 133.93. Group IIA-2 : 437.75 ± 54.83. Group IIB: 408.00 ± 125.39. Group IIC: 377.38 ± 104.50. Group IID: 350.87 ± 70.60. Group IIA-2 consisted of patients whose lesions were passive stage.

Omalizumab was given to group IIB and IIC (225- 375 MG) and gradually was ceased and continued with desloratadin 1x1. Group IID patients were under omalizumab medication only.

The significant DD difference was observed between Group IIA-1 and Group-IID (p<0.05), (P=0.015). In the IIA-1 group there was a significant positive correlation between DD and age (p=0.008, r=0.848, p<0.005).

Page 10: D-DIMER LEVELS decreased  in severe allergic asthma and chronic urticaria patients with the  omalizumab treatment

Biomaterials Research - Manfred MaitzD-dimer

Extrinsic pathway of coagulation is activated in responce to high level of circulatory IgE. Best example of this purported relationship is the correlation between higher TF expression and vasculitis degree that has been seen in Hyper IgE Syndrome.

After omalizumab therapy, significant decrease of the levels of DD shows the importance of procoagulant state in allergic patients. We also believe that DD may also have an important role for the relationship between IgE and extrinsic pathway in the endothelial cells.

Mediators and cells classically involved in procoagulant and anticoagulant pathways altogether play a role in SPA and CU pathophysiology and omalizumab effect.

Page 11: D-DIMER LEVELS decreased  in severe allergic asthma and chronic urticaria patients with the  omalizumab treatment

Biomaterials Research - Manfred Maitz

Page 12: D-DIMER LEVELS decreased  in severe allergic asthma and chronic urticaria patients with the  omalizumab treatment

Biomaterials Research - Manfred Maitz

Page 13: D-DIMER LEVELS decreased  in severe allergic asthma and chronic urticaria patients with the  omalizumab treatment

Biomaterials Research - Manfred MaitzYalcin AD. Evaluation of Homocysteine, Eosinophil Cationic Peptide, 25(OH) Vitamin D, and Immune Modulator OX-2 Levels in Moderate Allergic Asthma Patients: Association with Biological Treatment (Anti-IgE )& Disease Activity.

25(OH)D triggers a Hcy metabolizing enzyme and data from the Longitudinal Aging Study Amsterdam suggested a correlation between vitamin D status and Hcy levels.In vitro and in vivo studies showed that Hcy has an ability of influencing inflammatory cytokine/chemokine production and it might be through peripheral blood monocytes and monocyte-derived macrophages. Thus, Hcy appears to have immunomodulating and pro-inflammatory activities.

Hcy (mmol/ml) 28.98 ±3.46 23.22 ±1.87 19.17 ±3.24 p<0.05

Page 14: D-DIMER LEVELS decreased  in severe allergic asthma and chronic urticaria patients with the  omalizumab treatment

Biomaterials Research - Manfred Maitz

Page 15: D-DIMER LEVELS decreased  in severe allergic asthma and chronic urticaria patients with the  omalizumab treatment

Biomaterials Research - Manfred Maitz

Page 16: D-DIMER LEVELS decreased  in severe allergic asthma and chronic urticaria patients with the  omalizumab treatment

Biomaterials Research - Manfred MaitzOUR RESEARCH GROUPOUR RESEARCH GROUP

Dr. CHANG, SAADET, BETUL, SEDA, AYKUT, DONIC, ALFUR, ART, JAMES, REBECCA, LEO

Page 17: D-DIMER LEVELS decreased  in severe allergic asthma and chronic urticaria patients with the  omalizumab treatment

Biomaterials Research - Manfred Maitz Ignore those who say you do not suck. They said to me jerks. I gave shred the hands of atoms Special Theory of Relativity (1905), Relativity (1920 and 1950), General Theory of Relativity (1916), Investigations on Theory of Brownian Movement (1926), and The Evolution of Physics (1938). Among his non-scientific works, About Zionism (1930), Why War? (1933), My Philosophy (1934), and Out of My Later Years (1950).